RT Journal Article
SR Electronic
T1 Analysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine candidate
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.11.16.384594
DO 10.1101/2020.11.16.384594
A1 Juliane Brun
A1 Snežana Vasiljevic
A1 Bevin Gangadharan
A1 Mario Hensen
A1 Anu V. Chandran
A1 Michelle L. Hill
A1 J.L. Kiappes
A1 Raymond A. Dwek
A1 Dominic S. Alonzi
A1 Weston B. Struwe
A1 Nicole Zitzmann
YR 2020
UL http://biorxiv.org/content/early/2020/11/16/2020.11.16.384594.abstract
AB Severe acute respiratory syndrome coronavirus 2 is the causative pathogen of the COVID-19 pandemic which as of Nov 15, 2020 has claimed 1,319,946 lives worldwide. Vaccine development focuses on the viral trimeric spike glycoprotein as the main target of the humoral immune response. Viral spikes carry glycans that facilitate immune evasion by shielding specific protein epitopes from antibody neutralisation. Immunogen integrity is therefore important for glycoprotein-based vaccine candidates. Here we show how site-specific glycosylation differs between virus-derived spikes and spike proteins derived from a viral vectored SARS-CoV-2 vaccine candidate. We show that their distinctive cellular secretion pathways result in different protein glycosylation and secretion patterns, which may have implications for the resulting immune response and future vaccine design.Competing Interest StatementW.B.S. is a shareholder and consultant to Refeyn Ltd. All other authors declare no conflict of interest.